Cargando…
Evidence or no evidence for essential fatty acids in the treatment of autism spectrum disorders?
Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders that affect social communication, behavior, and sensory processing, in which PUFAs are considered important. This mini-review article aims to investigate the current evidence regarding the use of essential fatty acids (EFAs...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505929/ https://www.ncbi.nlm.nih.gov/pubmed/37727635 http://dx.doi.org/10.3389/fnut.2023.1251083 |
_version_ | 1785107011698950144 |
---|---|
author | Pancheva, Rouzha Zlatanova Nikolova, Silviya Serbezova, Asena Zaykova, Krassimira Zhelyazkova, Desislava Dimitrov, Lubomir |
author_facet | Pancheva, Rouzha Zlatanova Nikolova, Silviya Serbezova, Asena Zaykova, Krassimira Zhelyazkova, Desislava Dimitrov, Lubomir |
author_sort | Pancheva, Rouzha Zlatanova |
collection | PubMed |
description | Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders that affect social communication, behavior, and sensory processing, in which PUFAs are considered important. This mini-review article aims to investigate the current evidence regarding the use of essential fatty acids (EFAs) in the treatment of autism spectrum disorders (ASDs). The study examines various research studies, related to EFAs, their benefits, and their role in ASD treatment. The article focuses on exploring the potential mechanisms underlying the effects of EFAs on ASDs, including their anti-inflammatory, antioxidant, and neuroprotective properties. Furthermore, the study discusses limitations and challenges associated with the use of EFAs in ASD treatment, including variability in dosage and duration of treatment. The results of this review indicate that while some studies suggest a positive effect of EFAs on ASD symptoms, there is currently insufficient evidence to support their routine use as a stand-alone treatment for ASD. The need for further research to better understand the potential benefits and limitations of EFAs in ASD treatment is highlighted. |
format | Online Article Text |
id | pubmed-10505929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105059292023-09-19 Evidence or no evidence for essential fatty acids in the treatment of autism spectrum disorders? Pancheva, Rouzha Zlatanova Nikolova, Silviya Serbezova, Asena Zaykova, Krassimira Zhelyazkova, Desislava Dimitrov, Lubomir Front Nutr Nutrition Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders that affect social communication, behavior, and sensory processing, in which PUFAs are considered important. This mini-review article aims to investigate the current evidence regarding the use of essential fatty acids (EFAs) in the treatment of autism spectrum disorders (ASDs). The study examines various research studies, related to EFAs, their benefits, and their role in ASD treatment. The article focuses on exploring the potential mechanisms underlying the effects of EFAs on ASDs, including their anti-inflammatory, antioxidant, and neuroprotective properties. Furthermore, the study discusses limitations and challenges associated with the use of EFAs in ASD treatment, including variability in dosage and duration of treatment. The results of this review indicate that while some studies suggest a positive effect of EFAs on ASD symptoms, there is currently insufficient evidence to support their routine use as a stand-alone treatment for ASD. The need for further research to better understand the potential benefits and limitations of EFAs in ASD treatment is highlighted. Frontiers Media S.A. 2023-08-31 /pmc/articles/PMC10505929/ /pubmed/37727635 http://dx.doi.org/10.3389/fnut.2023.1251083 Text en Copyright © 2023 Pancheva, Nikolova, Serbezova, Zaykova, Zhelyazkova and Dimitrov. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Nutrition Pancheva, Rouzha Zlatanova Nikolova, Silviya Serbezova, Asena Zaykova, Krassimira Zhelyazkova, Desislava Dimitrov, Lubomir Evidence or no evidence for essential fatty acids in the treatment of autism spectrum disorders? |
title | Evidence or no evidence for essential fatty acids in the treatment of autism spectrum disorders? |
title_full | Evidence or no evidence for essential fatty acids in the treatment of autism spectrum disorders? |
title_fullStr | Evidence or no evidence for essential fatty acids in the treatment of autism spectrum disorders? |
title_full_unstemmed | Evidence or no evidence for essential fatty acids in the treatment of autism spectrum disorders? |
title_short | Evidence or no evidence for essential fatty acids in the treatment of autism spectrum disorders? |
title_sort | evidence or no evidence for essential fatty acids in the treatment of autism spectrum disorders? |
topic | Nutrition |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505929/ https://www.ncbi.nlm.nih.gov/pubmed/37727635 http://dx.doi.org/10.3389/fnut.2023.1251083 |
work_keys_str_mv | AT panchevarouzhazlatanova evidenceornoevidenceforessentialfattyacidsinthetreatmentofautismspectrumdisorders AT nikolovasilviya evidenceornoevidenceforessentialfattyacidsinthetreatmentofautismspectrumdisorders AT serbezovaasena evidenceornoevidenceforessentialfattyacidsinthetreatmentofautismspectrumdisorders AT zaykovakrassimira evidenceornoevidenceforessentialfattyacidsinthetreatmentofautismspectrumdisorders AT zhelyazkovadesislava evidenceornoevidenceforessentialfattyacidsinthetreatmentofautismspectrumdisorders AT dimitrovlubomir evidenceornoevidenceforessentialfattyacidsinthetreatmentofautismspectrumdisorders |